^
    Back
    Association details:
    Biomarker:NUP214-ABL1 rearrangement
    Cancer:T Acute Lymphoblastic Leukemia
    Drug:dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2019
    Title:

    Phospho-Proteomic Profiling of T-Cell Acute Lymphoblastic Leukemia Identifies Specific Kinase Activation Signatures That Can Predict Response to Targeted Therapy

    Published date:
    11/06/2019
    Excerpt:
    Surprisingly, only the cell lines with known genetic kinases aberrations-e.g. HSB-2 (TCRB-LCK translocated) and ALL-SIL (NUP214-ABL1 rearranged)-showed strong sensitivity to dasatinib.
    DOI:
    https://doi.org/10.1182/blood-2019-122898